Jacobio Pharma’s Glecirasib Receives the NMPA’s Breakthrough Therapy Designation for the Treatment of Pancreatic Cancer
Shots:
- The NMPA has granted BTD to Jacobio's glecirasib (KRAS G12C inhibitor) for the treatment of patients with pancreatic cancer with a KRAS G12C mutation who have progressed after frontline standard care treatment. The BTD was based on the clinical efficacy and safety data from ongoing clinical trials of gleciracib
- Gleciracib also received BTD in Dec 2022 for 2L setting and beyond of advanced or metastatic NSCLC patients with KRAS G12C mutation
- Additionally, the therapy is currently being studied in the P-I/II clinical trials for patients with advanced solid tumors harboring KRAS G12C mutation in China, the US, and the EU
Ref: Prnewwire | Image: Jacobio
Related News:- Jacobio Entered into a Clinical Collaboration with Merck to Evaluate JAB-BX102 + Keytruda (pembrolizumab) for Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
